Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.68 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL28780977 | 0.98 | CAMK2A (0.66) | CAMK2ACXCL8CHRM1HRH1FFAR1 | |
| SCHEMBL9288801 | 0.92 | CAMK2A (0.63) | CAMK2ACXCL8CHRM1HRH1FFAR1 | |
| SCHEMBL8969152 | 0.91 | CAMK2A (0.62) | CAMK2ACXCL8CHRM1HRH1FFAR1 | |
| SCHEMBL11097326 | 0.90 | CXCL8 (0.79) | CAMK2ACXCL8CHRM1AKR1B1L3MBTL1 | |
| SCHEMBL2353783 | 0.90 | CAMK2A (0.69) | CAMK2ACXCL8CHRM1HRH1FFAR1 | |
| SCHEMBL11335218 | 0.90 | CXCL8 (0.59) | CAMK2ACXCL8CHRM1FFAR1AKR1B1 | |
| SCHEMBL10561756 | 0.90 | CXCL8 (0.69) | CAMK2ACXCL8CHRM1HRH1FFAR1 | |
| SCHEMBL2555874 | 0.88 | CXCL8 (0.58) | CAMK2ACXCL8CHRM1HRH1FFAR1 | |
| SCHEMBL872958 | 0.88 | CXCL8 (0.67) | CAMK2ACXCL8CHRM1FFAR1SLC6A2 | |
| Ammonia Solution, Strong SCHEMBL872909 | 0.87 | CHRM1 (0.65) | CAMK2ACXCL8CHRM1FFAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199259-B2 | Resolution of α-(phenoxy)phenylacetic acid derivatives | METABOLEX, INC. (US) | 2007-04-03 | — | — | US | claimed |
| EP-1635809-A4 | RESOLUTION OF ALPHA-(PHENOXY)PHENYLACETIC ACID DERIVATIVES | METABOLEX INC (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1635809-A1 | RESOLUTION OF ALPHA-(PHENOXY)PHENYLACETIC ACID DERIVATIVES | Metabolex, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050033084-A1 | Resolution of alpha-(phenoxy)phenylacetic acid derivatives | METABOLEX, INC. (US) | 2005-02-10 | — | — | US | claimed |
| WO-2004112774-A1 | RESOLUTION OF α-(PHENOXY)PHENYLACETIC ACID DERIVATIVES | METABOLEX, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-6469195-B1 | SUITABLE FOR USE AS CROP PROTECTION AGENTS AGAINST HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-22 | — | — | US | claimed |
| JP-2001501449-A | — | — | 2001-02-06 | — | — | JP | claimed |
| EP-0873334-A1 | PROCESS FOR THE PREPARATION OF AN ENDOTHELIN ANTAGONIST | Merck & Co., Inc. (a New Jersey corp.) (US) | 1998-10-28 | — | — | EP | claimed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | claimed |
| US-5688974-A | Process for the preparation of an endothelin antagonist | MERCK & CO., INC. (US) | 1997-11-18 | — | — | US | claimed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | claimed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| WO-1997021700-A1 | PROCESS FOR THE PREPARATION OF AN ENDOTHELIN ANTAGONIST | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | claimed |
| EP-0278176-B1 | Compounds having antitumour and antibacterial properties | WARNER LAMBERT CO (US) | 1994-03-09 | — | — | EP | claimed |
| EP-0278176-A2 | Compounds having antitumour and antibacterial properties | WARNER-LAMBERT COMPANY (US) | 1988-08-17 | — | — | EP | claimed |
| JP-54122284-A | — | — | None | — | — | JP | disclosed |
| US-12458624-B2 | Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides | DHANOA DALJIT SINGH (US) | 2025-11-04 | — | — | US | disclosed |
| US-4310544-A | Hydroxyacetic acid derivatives with anti-arthritic properties | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-01-12 | — | — | US | disclosed |
| EP-0009306-A1 | Anti-arthritic hydroxyacetic acid derivatives, pharmaceutical compositions thereof, and processes for their manufacture | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-04-02 | — | — | EP | disclosed |
| JP-S54122284-A | DIBENZB,FOXEPIN DERIVATIVE | DAINIPPON PHARMACEUT CO LTD | 1979-09-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033084-A1 | Resolution of alpha-(phenoxy)phenylacetic acid derivatives | PAH, PDGFA, PDGFRA | CAMK2A 2205/4885CXCL8 4536/4885CHRM1 611/4885 |
| US-12458624-B2 | Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides | AGTR2, AGTR1, EDNRA | CAMK2A 1505/4885CXCL8 4697/4885CHRM1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.